Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Sales (2016 - 2025)

Ligand Pharmaceuticals' Return on Sales history spans 15 years, with the latest figure at 0.75% for Q4 2025.

  • For Q4 2025, Return on Sales rose 148.0% year-over-year to 0.75%; the TTM value through Dec 2025 reached 0.46%, up 65.0%, while the annual FY2025 figure was 0.46%, 49.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.75% at Ligand Pharmaceuticals, down from 1.02% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.02% in Q3 2025 and bottomed at 0.94% in Q1 2025.
  • The 5-year median for Return on Sales is 0.07% (2022), against an average of 0.05%.
  • The largest annual shift saw Return on Sales crashed -71bps in 2024 before it soared 148bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 0.04% in 2021, then plummeted by -49bps to 0.06% in 2022, then skyrocketed by 78bps to 0.01% in 2023, then crashed by -5627bps to 0.73% in 2024, then surged by 203bps to 0.75% in 2025.
  • Per Business Quant, the three most recent readings for LGND's Return on Sales are 0.75% (Q4 2025), 1.02% (Q3 2025), and 0.1% (Q2 2025).